Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis
- 1 July 2003
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 9 (4), 302-312
- https://doi.org/10.1097/00130404-200307000-00013
Abstract
Based largely on in vitro inve stigations and animal studies, investigators believe that disruptions of transforming growth factor-β (TGF-β) signaling contribute to the development and progression of human colorectal cancer. The purpose of this study was to directly assess the status of the TGF-β signaling pathway in colorectal cancer and determine the effects of its disruption on clinical behavior and outcome. Smad proteins are the principal intracellular components of the TGF-β signaling pathway. We conducted a high-throughput analysis of the expression patterns of Smad2, phosphorylated (activated) Smad2 (pSmad2), and Smad4 in more than 600 human colorectal cancer specimens assembled in tissue microarrays. The vast majority (93.8%; 95% Cl: 92%–96%) of colorectal cancers expressed phosphorylated Smad2, indicating the ability of the tumors to survive and proliferate within a microenvironment that contains bioactive TGF-β. Twelve of 633 (1.9%; 95% Cl: 1%–3%) cases failed to express Smad2, and 15 of 641 (2.3%; 95% Cl: 1%–4%) cases failed to express Smad4. Moreover, 29 of 615 (4.7%; 95% Cl: 3%–7%) of cases expressed Smad2 but not its activated form (pSmad2), suggesting the presence of a TGF-β receptor defect. Based on an analysis of 577 cases for which clinical outcome information was available, failure to express Smad2, pSmad2, or Smad4 was associated with advanced stage disease, the presence of lymph node metastases, and a significantly shorter overall survival (median survival: 35 vs 58 months). Loss of Smad activation and/or expression occurs in approximately 10% of colorectal cancers. This subset has a poor prognosis because of its association with advanced disease and the presence of lymph node metastases at diagnosis.Keywords
This publication has 44 references indexed in Scilit:
- Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in miceOncogene, 2000
- Smad3 Mutant Mice Develop Metastatic Colorectal CancerCell, 1998
- TGF-β1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expressionOncogene, 1998
- TGF-β SIGNAL TRANSDUCTIONAnnual Review of Biochemistry, 1998
- Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc GenesCell, 1998
- CANCER BIOLOGY: Type II TGFβ receptor expression in intestinal cell lines and in the intestinal tractCarcinogenesis: Integrative Cancer Research, 1996
- Cytokine modulation of intestinal epithelial cell restitution: Central role of transforming growth factor βGastroenterology, 1993
- Transforming growth factor β regulation of migration in wounded rat intestinal epithelial monolayersGastroenterology, 1993
- Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor β inhibits proliferation and stimulates differentiationBiochemical and Biophysical Research Communications, 1987
- Type beta transforming growth factor: a bifunctional regulator of cellular growth.Proceedings of the National Academy of Sciences, 1985